Adaptin Bio (APTN) Common Equity (2022 - 2026)

Adaptin Bio has disclosed Common Equity across 5 years of filings, most recently posting -$1.8 million for Q1 2026.

• Quarterly Common Equity fell 201.74% year-over-year to -$1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.8 million (down 201.74% YoY) and the FY2025 annual result came in at -$1.5 million, up 63.67% from the prior year.
• Common Equity eased to -$1.8 million in Q1 2026, from -$1.5 million in the prior quarter.
• Across five years, Common Equity topped out at $1.7 million in Q1 2025 and bottomed at -$4.1 million in Q4 2024.
• The 5-year median for Common Equity is -$929318.5 (2023), against an average of -$990960.8.
• Year-over-year, Common Equity plunged 5865.06% in 2024 and surged 232.52% in 2025.
• Adaptin Bio's Common Equity stood at -$27304.0 in 2022, then tumbled by 3480.28% to -$977559.0 in 2023, then tumbled by 319.42% to -$4.1 million in 2024, then soared by 63.67% to -$1.5 million in 2025, then fell by 19.21% to -$1.8 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered -$1.8 million, -$1.5 million, and -$881078.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.